| CCY | SZE(M) | TNR | MTY | RNK | MO | SP | FI | TYPE | BNCH | IPT | GDNC | SPRD | CPN | NIC | PRICE |
|---|
| USD | 300.000 | 2 | Mar-24 | Sr. Unsecured | Baa1 | BBB | - | Floating | SOFR | SOFR+Equiv | SOFR+Equiv | 89 | SOFR+89 | - | 100.00000 |
| USD | 700.000 | 2 | Mar-24 | Sr. Unsecured | Baa1 | BBB | - | Fixed | Tsy | T+110 a | T+90 | 90 | 3.02% | - | 100.00000 |
| USD | 1,750.000 | 3 | Mar-25 | Sr. Unsecured | Baa1 | BBB | - | Fixed | Tsy | T+110 a | T+90 | 90 | 3.13% | - | 99.73900 |
| USD | 2,000.000 | 5 | Mar-27 | Sr. Unsecured | Baa1 | BBB | - | Fixed | Tsy | T+130 a | T+110 | 110 | 3.38% | - | 99.78100 |
| USD | 1,000.000 | 7 | Mar-29 | Sr. Unsecured | Baa1 | BBB | - | Fixed | Tsy | T+140 a | T+115 | 115 | 3.38% | - | 99.27300 |
| USD | 2,000.000 | 10 | Mar-32 | Sr. Unsecured | Baa1 | BBB | - | Fixed | Tsy | T+160 a | T+135 | 135 | 3.63% | - | 99.85000 |
| USD | 1,000.000 | 30 | Mar-52 | Sr. Unsecured | Baa1 | BBB | - | Fixed | Tsy | T+190 a | T+158 | 158 | 4.00% | - | 98.16400 |
Tranche Comments
2 yr: Book size: 1000; Redemption: 2023-03-24; Registration: 144A/Reg S; Comments: US$300m 2yr FRN (3/24/24) at 100, floats at SOFR+89. CoC: 101%;
2 yr: Book size: 2250; Redemption: 2023-03-24; Registration: 144A/Reg S; Comments: US$700m 3.024% cpn 2yr FXD (3/24/24) at 100, yld 3.024%. Spread: T+90bp. MWC T+15bp. CoC: 101%;
3 yr: Book size: 3500; Registration: 144A/Reg S; Comments: US$1.75bn 3.125% cpn 3yr FXD(3/24/25) at 99.739, yld 3.217%. Spread: T+90bp. MWC T+15bp. CoC: 101%;
5 yr: Book size: 6000; Registration: 144A/Reg S; Comments: US$2bn 3.375% cpn 5yr (3/24/27) at 99.781, yld 3.423%. Spread: T+110bp. MWC T+20bp. CoC: 101%;
7 yr: Book size: 4500; Registration: 144A/Reg S; Comments: US$1bn 3.375% cpn 7yr (3/24/29) at 99.273, yld 3.496%. Spread: T+115bp. MWC T+20bp. CoC: 101%;
10 yr: Book size: 8000; Registration: 144A/Reg S; Comments: US$2bn 3.625% cpn 10yr(3/24/32) at 99.850, yld 3.643% T+135bp. MWC T+25bp. CoC: 101%;
30 yr: Book size: 8500; Registration: 144A/Reg S; Comments: US$1bn 4.00% cpn 30yr (3/24/52) at 98.164, yld 4.107% T+158bp. MWC T+25bp. CoC: 101%;
Deal Comments
Joint Bookrunners: BAM(B&D) (2 yr, 3 yr, 5 yr, 7 yr, 10 yr), CTI(B&D) (30 yr), GSC, HSB, MIZ
Guarantor(s)
GlaxoSmithKline plc, Haleon plc
Use of Proceeds
To fund pre-demerger dividends